首页> 中文期刊> 《中国医药指南》 >帕利哌酮与奥氮平对首发精神分裂症患者血浆瘦素和胰岛素水平的影响

帕利哌酮与奥氮平对首发精神分裂症患者血浆瘦素和胰岛素水平的影响

         

摘要

目的:探讨帕利哌酮与奥氮平对首发精神分裂症患者血浆瘦素和胰岛素水平的影响。方法首发精神分裂症患者60例,随机分为帕利哌酮治疗组(30例)和奥氮平治疗组(30例),30例健康成人为对照组,治疗组在治疗前和治疗后6周末测定血浆瘦素和胰岛素水平。结果治疗后奥氮平组瘦素含量较治疗前明显升高,治疗前后胰岛素水平奥氮平组比较有统计学差异,治疗后奥氮平组BMI与治疗前比较有统计学意义,奥氮平组BMI增加值与帕利哌酮组有统计学差异(P<0.05)。结论奥氮平对血浆瘦素、胰岛素水平和BMI均有明显影响,而帕利哌酮则影响不明显。%Objective To explore the effects paliperidone and olanzapine on plasma leptin and insulin in first-episode schizophrenic patients. Methods Sixty first-episode schizophrenics were randomly divided into two groups, which were treated with olanzapine and paliperidone respectively. The plasma leptin and insulin concentration was measured with radioimmunoassay pretreatment and 6 weeks post-treatment. Results Plasma leptin level of post-treatment increased compared with that of pre-treatment in olanzapine group, plasma insulin level of post-treatment increased compared with that of pre-treatment in olanzapine group, BMI after treatment increased compared with that before treatmentres in olanzapine group (P<0.05). Conclusion Olanzapine have significant effects on plasma leptin and insulin concentration and BMI, but paliperidone has no obvious effect on plasma leptin and insulin levels and BMI.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号